Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...
Too Old to Operate14d
Pulmonary Vein Isolation Yields Reduction in A-Fib Burden
THURSDAY, Sept. 5, 2024 (HealthDay News) — For patients with symptomatic paroxysmal or persistent atrial fibrillation, pulmonary vein isolation results in a significant and clinically important ...
The American Journal of Managed Care15d
Emerging Trends in Alzheimer Disease Detection and Treatment
Alzheimer disease research is yielding breakthroughs with blood tests and brain scans that can enhance early diagnosis, while ...
Yahoo Finance16d
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
The topline results showed that neither the trial's primary endpoint (the Global Statistical Test (GST), a combination ... AD patients not on acetylcholinesterase inhibitors (AChEIs) compared ...
Medscape25d
TYK2 Inhibitor Shows Promise for Moderate to Severe Psoriasis
Zasocitinib, a tyrosine kinase 2 (TYK2) inhibitor, at oral doses of ≥ 5 mg led to greater skin clearance than placebo over a period of 12 weeks, in a phase 2b study. Researchers performed a ...
Frontiers28d
Expression and characterization of recombinant antibodies against H7 subtype avian influenza virus and their diagnostic potential
Recombinant antibodies were purified from the cell culture medium, and their potential applications were evaluated using hemagglutination inhibition (HI), western blotting (WB), confocal microscopy, ...
Medscape29d
Rationale for Combining Glutamatergic and Cholinergic Approaches in the Symptomatic Treatment of Alzheimer's Disease
The efficacy of individual treatment approaches with contrasting cholinergic and glutamatergic mechanisms of action prompted investigation of the effects of targeting both systems for the ...